8-KOther EventsExhibits & Filings

CVS HEALTH Corp 8-K Report, Corporate Update (Sep 10, 2008)

Filed September 10, 2008For Securities:CVS

Summary

CVS Health Corporation (CVS) announced on September 5, 2008, the execution of an Underwriting Agreement to issue and sell $350 million of Floating Rate Notes due September 10, 2010. The net proceeds from this offering are estimated to be approximately $348.5 million after deducting underwriting discounts and estimated expenses. These proceeds are expected to bolster the company's financial flexibility and support its operational and strategic initiatives. This debt issuance occurs in the context of CVS's ongoing activities, including its proposed acquisition of Longs Drug Stores Corporation, where some of the underwriters or their affiliates have acted as financial advisors and are participants in the company's bridge loan facility. The net proceeds will reduce the outstanding commitment under its Form S-3 registration statement, indicating a strategic use of capital.

Key Highlights

  • 1CVS Caremark Corporation issued $350 million in Floating Rate Notes due September 10, 2010.
  • 2The net proceeds from the note issuance are estimated at approximately $348.5 million.
  • 3The offering was conducted under the company's existing Registration Statement on Form S-3.
  • 4The debt issuance is governed by a Senior Indenture dated August 15, 2006.
  • 5Underwriters and their affiliates have provided past and potentially future investment banking services to CVS.
  • 6Certain underwriters are involved as financial advisors and lenders in relation to the proposed acquisition of Longs Drug Stores Corporation.
  • 7The net proceeds will reduce the outstanding commitment under the company's Form S-3 registration statement.

Frequently Asked Questions

This 8-K filing primarily announces CVS Caremark Corporation's entry into an Underwriting Agreement to issue and sell $350 million of Floating Rate Notes due September 10, 2010, and provides details regarding the terms of the offering and the intended use of proceeds.

CVS Health raised $350 million in principal amount through the issuance of its Floating Rate Notes. After deducting underwriting discounts and estimated expenses, the net proceeds are approximately $348.5 million.

The involvement of some underwriters and their affiliates as financial advisors and bridge loan participants in CVS's proposed acquisition of Longs Drug Stores Corporation suggests potential synergies or ongoing business relationships. It also highlights the integrated financial services provided by these institutions to the company.

While not explicitly detailed beyond bolstering financial flexibility, the net proceeds will reduce the outstanding commitment under the company's Form S-3 registration statement. This indicates the funds are intended for general corporate purposes or to support strategic initiatives, such as the acquisition of Longs Drug Stores.